NextCell Pharma AB (OSTO:NXTCL) ROCE % : -62.68% (As of Feb. 2024)

View and export this data going back to 2017. Start your Free Trial

What is NextCell Pharma AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. NextCell Pharma AB's annualized ROCE % for the quarter that ended in Feb. 2024 was -62.68%.

NextCell Pharma AB ROCE % Historical Data

The historical data trend for NextCell Pharma AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextCell Pharma AB ROCE % Chart

NextCell Pharma AB Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

ROCE %

Get a 7-Day Free Trial

-121.14

-68.63

-27.39

-25.64

-40.52

NextCell Pharma AB Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
ROCE %	Get a 7-Day Free Trial															-44.14	-47.25	-41.34	-52.91	-62.68

NextCell Pharma AB ROCE % Calculation

NextCell Pharma AB's annualized ROCE % for the fiscal year that ended in Aug. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Aug. 2023 )		(A: Aug. 2022 )		(A: Aug. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Aug. 2023 )		(A: Aug. 2022 )		(A: Aug. 2023 )
	=	-39.809	/	( ( (124.655 - 6.932)	+	(88.827 - 10.08) )	/ 2 )
	=	-39.809	/	( (117.723	+	78.747)	/ 2 )
	=	-39.809	/	98.235
	=	-40.52 %

NextCell Pharma AB's ROCE % of for the quarter that ended in Feb. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Feb. 2024 )		(Q: Nov. 2023 )		(Q: Feb. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Feb. 2024 )		(Q: Nov. 2023 )		(Q: Feb. 2024 )
	=	-40.368	/	( ( (81.218 - 11.861)	+	(70.542 - 11.095) )	/ 2 )
	=	-40.368	/	( ( 69.357	+	59.447 )	/ 2 )
	=	-40.368	/	64.402
	=	-62.68 %

(1) Note: The EBIT data used here is four times the quarterly (Feb. 2024) EBIT data.

NextCell Pharma AB (OSTO:NXTCL) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

NextCell Pharma AB ROCE % Related Terms

Thank you for viewing the detailed overview of NextCell Pharma AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

NextCell Pharma AB (OSTO:NXTCL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCell Pharma AB (OSTO:NXTCL) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

65G:Germany

Address

Karolinska Institutet Science Park, Halsovagen 7, Huddinge, SWE, 14157

Website

http://www.nextcellpharma.com

NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.

NextCell Pharma AB (OSTO:NXTCL) Headlines

No Headlines